BRIDGEBIO PHARMA, INC. (BBIO)
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
📈 **POSITIVE** • Low confidence analysis (57%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (81%) **Content type:** Clinical